ShanXi C&Y Pharmaceutical Group Co.,LTD.

SZSE:300254 Stock Report

Market Cap: CN¥2.2b

ShanXi C&Y Pharmaceutical GroupLTD Past Earnings Performance

Past criteria checks 2/6

ShanXi C&Y Pharmaceutical GroupLTD has been growing earnings at an average annual rate of 22.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 6.3% per year. ShanXi C&Y Pharmaceutical GroupLTD's return on equity is 13.6%, and it has net margins of 9.9%.

Key information

22.5%

Earnings growth rate

23.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-6.3%
Return on equity13.6%
Net Margin9.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Recent updates

Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet

Sep 30
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet

ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

May 27
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

Mar 25
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues

ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Mar 06
ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Revenue & Expenses Breakdown

How ShanXi C&Y Pharmaceutical GroupLTD makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300254 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248368343747
30 Jun 248358343655
31 Mar 248064644353
31 Dec 237992545350
30 Sep 23767-10746557
30 Jun 23790-12049255
31 Mar 23820-11951454
01 Jan 23829-11953555
30 Sep 22847-11155452
30 Jun 22878-11057753
31 Mar 22899-9458557
01 Jan 22930-9159957
30 Sep 21966-14465172
30 Jun 21911-19165777
31 Mar 21920-21870572
31 Dec 20848-26269872
30 Sep 20861-16270457
30 Jun 20968-11276749
31 Mar 201,029-5878247
31 Dec 191,132581849
30 Sep 191,1842981543
30 Jun 191,1543277250
31 Mar 191,1192074055
31 Dec 181,136774854
30 Sep 181,0922071862
30 Jun 181,0581867370
31 Mar 181,0242363154
31 Dec 179392255743
30 Sep 178912551326
30 Jun 17834314850
31 Mar 17791304570
31 Dec 16746304380
30 Sep 16732224430
30 Jun 16704244270
31 Mar 16683224160
31 Dec 15684234090
30 Sep 15669403880
30 Jun 15666403890
31 Mar 15660413850
31 Dec 14654413830
30 Sep 14646383610
30 Jun 14598333290
31 Mar 14547292950
31 Dec 13514272770

Quality Earnings: 300254 has a large one-off gain of CN¥48.5M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300254 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300254 has become profitable over the past 5 years, growing earnings by 22.5% per year.

Accelerating Growth: 300254 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 300254 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 300254's Return on Equity (13.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ShanXi C&Y Pharmaceutical Group Co.,LTD. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Jun LingPing An Securities Co. Ltd.
Xiao PengTX Investment Consulting Co., Ltd.